Our research analysts offer in-depth analysis of stocks across the market-cap spectrum, albeit with a particular focus on small- and midcap companies. We strive to identify best-of-breed companies that have promising long-term outlooks with attractive, sustainable earnings growth rates.

Technology analyst Mathew Pfau believes that digital freight matching (DFM) is a potentially massive market that has garnered a lot of attention from venture capital and private equity over the past several years.

With the robust efficacy of autologous CAR-T-cell therapies to date, the focus has shifted to commercial issues related to vein-to-vein time, manufacturing variability, shipping/chain-of-custody issues, and scalability over the long term. Allogeneic cell therapies (derived from a healthy donor) have the potential to address these issues by providing an enhanced speed to patient, availability, decreased cell variability, and streamlined manufacturing efficiencies.

This conference showcases the scientists and clinicians driving the advancements in the field of cancer immunotherapy and is designed to facilitate discussion with the audience to further elucidate underlying mechanisms of biology and promising novel therapies.

Companies are increasingly turning to low-code/no-code application development platforms that democratize the development process and give business users the ability to develop applications themselves with minimal or no assistance from IT.

Healthcare analyst John Kreger attended CPhI Worldwide, the world’s largest trade fair for pharmaceutical contract manufacturing. At the event, he had the opportunity to meet with public and private players in the contract development and manufacturing (CDMO) space. 

The commercial real estate (CRE) services industry is growing relatively quickly and represents a broad variety of services provided to property managers, investors, and tenants/occupiers of commercial real estate.

AI has experienced multiple cycles of extraordinary hype, yet with the confluence of a few recent trends, we believe the pieces are now in place for AI to unleash a new wave of disruption.

The U.S. bottled water market is $16 billion (producer revenue) and forecast to grow at a compound annual rate of 8%. More broadly, the U.S. non-alcoholic beverage market is $180 billion and has grown at a low-single-digit rate.

The Biotechnology Research Team co-hosted our eighth annual conference in New York with Maidstone Life Sciences. The two-day event was divided into four themes: Adoptive Cell Therapies, Jump-Starting the Immune System, Next-Generation Approaches, and Immunotherapy Combinations.

Analyst Ryan Daniels reports on a convergence of events that has rapidly pushed our thesis on consumerism in the healthcare marketplace forward. We now believe a tipping point has arrived that is markedly changing the U.S. healthcare landscape.

 1 2 3 4